Transmitted Drug Resistance in Nonsubtype B HIV-1 Infection

Overview

Journal HIV Ther

Publisher Future Medicine

Specialty Infectious Diseases

Date 2010 Feb 18

PMID 20161523

Citations 15

Authors

Philip A Chan

Rami Kantor

Affiliations

Soon will be listed here.

Abstract

HIV-1 nonsubtype B variants account for the majority of HIV infections worldwide. Drug resistance in individuals who have never undergone antiretroviral therapy can lead to early failure and limited treatment options and, therefore, is an important concern. Evaluation of reported transmitted drug resistance (TDR) is challenging owing to varying definitions and study designs, and is further complicated by HIV-1 subtype diversity. In this article, we discuss the importance of various mutation lists for TDR definition, summarize TDR in nonsubtype B HIV-1 and highlight TDR reporting and interpreting challenges in the context of HIV-1 diversity. When examined carefully, TDR in HIV-1 non-B protease and reverse transcriptase is still relatively low in most regions. Whether it will increase with time and therapy access, as observed in subtype-B-predominant regions, remains to be determined.

Citing Articles

Molecular Antiretroviral Resistance Markers of Human Immunodeficiency Virus-1 of CRF01_AE Subtype in Bali, Indonesia.

Budayanti N, Merati T, Bela B, Mahardika G Curr HIV Res. 2019; 16(5):374-382.

PMID: 30714528 PMC: 6446452. DOI: 10.2174/1570162X17666190204101154.

Early Presence of HIV-1 Subtype C in Washington, D.C.

Grossman Z, Rico S, Cone K, Shao W, Rehm C, Jones S AIDS Res Hum Retroviruses. 2018; 34(8):680-684.

PMID: 29936863 PMC: 6080110. DOI: 10.1089/AID.2018.0041.

A Phylogenetic Analysis of Human Immunodeficiency Virus Type 1 Sequences in Kiev: Findings Among Key Populations.

Fearnhill E, Gourlay A, Malyuta R, Simmons R, Ferns R, Grant P Clin Infect Dis. 2017; 65(7):1127-1135.

PMID: 28575385 PMC: 5850412. DOI: 10.1093/cid/cix499.

Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naïve persons in rural western Kenya.

Onywera H, Maman D, Inzaule S, Auma E, Were K, Fredrick H PLoS One. 2017; 12(2):e0171124.

PMID: 28178281 PMC: 5298248. DOI: 10.1371/journal.pone.0171124.

The prevalence of drug resistance among treatment-naïve HIV-1-infected individuals in China during pre- and post- 2004.

Li H, Chang S, Han Y, Zhuang D, Li L, Liu Y BMC Infect Dis. 2016; 16(1):605.

PMID: 27782811 PMC: 5080753. DOI: 10.1186/s12879-016-1928-x.

References

Marechal V, Jauvin V, Selekon B, Leal J, Pelembi P, Fikouma V . Increasing HIV type 1 polymorphic diversity but no resistance to antiretroviral drugs in untreated patients from Central African Republic: a 2005 study. AIDS Res Hum Retroviruses. 2006; 22(10):1036-44. DOI: 10.1089/aid.2006.22.1036. View

Wensing A, van de Vijver D, Angarano G, Asjo B, Balotta C, Boeri E . Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005; 192(6):958-66. DOI: 10.1086/432916. View

Caron M, Makuwa M, Souquiere S, Descamps D, Brun-Vezinet F, Kazanji M . Human immunodeficiency virus type 1 seroprevalence and antiretroviral drug resistance-associated mutations in miners in Gabon, central Africa. AIDS Res Hum Retroviruses. 2008; 24(9):1225-8. DOI: 10.1089/aid.2008.0097. View

Hemelaar J, Gouws E, Ghys P, Osmanov S . Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS. 2006; 20(16):W13-23. DOI: 10.1097/01.aids.0000247564.73009.bc. View

Weidle P, Kityo C, Mugyenyi P, Downing R, Kebba A, Pieniazek D . Resistance to antiretroviral therapy among patients in Uganda. J Acquir Immune Defic Syndr. 2001; 26(5):495-500. DOI: 10.1097/00126334-200104150-00017. View

Bennett D, Myatt M, Bertagnolio S, Sutherland D, Gilks C . Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther. 2008; 13 Suppl 2:25-36. View

Gazzard B, Anderson J, Babiker A, Boffito M, Brook G, Brough G . British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008; 9(8):563-608. DOI: 10.1111/j.1468-1293.2008.00636.x. View

Kantor R . Impact of HIV-1 pol diversity on drug resistance and its clinical implications. Curr Opin Infect Dis. 2006; 19(6):594-606. DOI: 10.1097/QCO.0b013e3280109122. View

Hammer S, Eron Jr J, Reiss P, Schooley R, Thompson M, Walmsley S . Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008; 300(5):555-70. DOI: 10.1001/jama.300.5.555. View

10.

Deeks S . Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet. 2003; 362(9400):2002-11. DOI: 10.1016/S0140-6736(03)15022-2. View

11.

Liao L, Xing H, Li X, Ruan Y, Zhang Y, Qin G . Genotypic analysis of the protease and reverse transcriptase of HIV type 1 isolates from recently infected injecting drug users in western China. AIDS Res Hum Retroviruses. 2007; 23(8):1062-5. DOI: 10.1089/aid.2007.0050. View

12.

Deroo S, Robert I, Fontaine E, Lambert C, Plesseria J, Arendt V . HIV-1 subtypes in Luxembourg, 1983-2000. AIDS. 2002; 16(18):2461-7. DOI: 10.1097/00002030-200212060-00012. View

13.

Watanaveeradej V, Benenson M, de Souza M, Sirisopana N, Nitayaphan S, Tontichaivanich C . Molecular epidemiology of HIV Type 1 in preparation for a Phase III prime-boost vaccine trial in Thailand and a new approach to HIV Type 1 genotyping. AIDS Res Hum Retroviruses. 2006; 22(8):801-7. DOI: 10.1089/aid.2006.22.801. View

14.

Agwale S, Zeh C, Paxinos E, Odama L, Pienazek D, Wambebe C . Genotypic and phenotypic analyses of human immunodeficiency virus type 1 in antiretroviral drug-naive Nigerian patients. AIDS Res Hum Retroviruses. 2006; 22(1):22-6. DOI: 10.1089/aid.2006.22.22. View

15.

Auswinporn S, Jenwitheesuk E, Panburana P, Sirinavin S, Vibhagool A, Chantratita W . Prevalence of HIV-1 drug resistance in antiretroviral-naive pregnant Thai women. Southeast Asian J Trop Med Public Health. 2003; 33(4):818-21. View

16.

Ananworanich J, Phanuphak N, de Souza M, Paris R, Arroyo M, Trichavaroj R . Incidence and characterization of acute HIV-1 infection in a high-risk Thai population. J Acquir Immune Defic Syndr. 2008; 49(2):151-5. DOI: 10.1097/QAI.0b013e318183a96d. View

17.

Petch L, Hoffman I, Jere C, Kazembe P, Martinson F, Chilongozi D . Genotypic analysis of the protease and reverse transcriptase of HIV type 1 subtype C isolates from antiretroviral drug-naive adults in Malawi. AIDS Res Hum Retroviruses. 2005; 21(9):799-805. DOI: 10.1089/aid.2005.21.799. View

18.

Soares E, Santos R, Pellegrini J, Sprinz E, Tanuri A, Soares M . Epidemiologic and molecular characterization of human immunodeficiency virus type 1 in southern Brazil. J Acquir Immune Defic Syndr. 2003; 34(5):520-6. DOI: 10.1097/00126334-200312150-00012. View

19.

Cornelissen M, van den Burg R, Zorgdrager F, Lukashov V, Goudsmit J . pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D. J Virol. 1997; 71(9):6348-58. PMC: 191908. DOI: 10.1128/JVI.71.9.6348-6358.1997. View

20.

Punzi G, Saracino A, Brindicci G, Scarabaggio T, Lagioia A, Angarano G . HIV infection and protease genetic diversity in a rural area of the Southern Central African Republic. J Med Virol. 2005; 77(4):457-9. DOI: 10.1002/jmv.20476. View